| Biomarker ID | 1914 |
| PMID | 30396985 |
| Year | 2018 |
| Biomarker | Prohibitin+ HSP27+ALDH6A1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Metastatic PCa: [HSP27 (2.01 fold); prohibitin (1.88 fold); GSTP1 (1.18 fold); fibrinogen β chain (2.68 fold); ALDH6A1 (2.89 fold);]Downregulated in Metastatic PCa [A1AT (0.84 fold) ; HSP60 (0.19 fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways inlcude (ALDH6A1): Branched-chain amino acid catabolism, Propanoate metabolism, Valine, leucine and isoleucine degradation, Inositol phosphate metabolism, Amino acid metabolism |
| Experiment | Survival Vs No Survival |
| Type of Biomarker | Prognostic |
| Cohort | 98 patients with metastatic Prostate Cancer were selected for analysis. 50 were alive and 48 were deceased |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.8525 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |